Endogenous interleukin-11 (IL-11) levels in newly diagnosed children with acquired severe aplastic anemia (SAA)

Cytokine
Erin M CockrellPediatric Aplastic Anemia Cooperative Trial #3 Investigators

Abstract

Impaired hematopoietic growth factor production is a hypothetical contributing factor to the development of acquired severe aplastic anemia (SAA). The serum levels of most hematopoietic cytokines in SAA patients are elevated. To measure interleukin-11 levels in newly diagnosed SAA children and attempt to correlate levels with disease severity and response to therapy. Following enrollment into a clinical study but prior to treatment, serum samples were obtained from 11 newly diagnosed children with acquired SAA. These samples were collected between May 2000 and September 2002. IL-11 levels were quantified utilizing an ELISA technique. Ten of the 11 patients had low or normal levels of IL-11 (<85 pg/mL) and one had an elevated level of 409 pg/mL (normal range 15-200 pg/mL). The production of IL-11 does not increase in response to thrombocytopenia in most children with SAA. The significance of this laboratory observation is not clear at this time. Further studies are warranted to determine what, if any, role this plays in the development of this disorder and if the administration of recombinant human IL-11 might be beneficial in the treatment of acquired SAA.

References

Jan 31, 1985·The New England Journal of Medicine·N C ZoumbosN S Young
Nov 1, 1993·Stem Cells·Y C Yang
Apr 2, 1999·European Journal of Gastroenterology & Hepatology·M Peck-RadosavljevicA Gangl
Sep 14, 1999·Leukemia·U S SchwertschlagA J Dorner
Oct 20, 1999·Annals of Hematology·M CremerM Ballmaier
Nov 25, 2000·British Journal of Haematology·C A SieffD G Nathan
May 29, 2002·Pediatric Research·Mary P McCloyNeil A Murray
Jan 25, 2003·Cytokine·Sylvie HermouetYannick Jacques

❮ Previous
Next ❯

Citations

Jan 5, 2010·Critical Reviews in Oncology/hematology·Jian Ping LiZhong Chao Han

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.